675 studies found for:    Herceptin
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
Condition: Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla];   Drug: Trastuzumab;   Drug: Docetaxel
2 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Condition: Metastatic Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg;   Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg;   Drug: Pertuzumab 420 mg
3 Completed
Has Results
Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Herceptin;   Drug: Navelbine;   Drug: Taxotere;   Drug: Carboplatin
4 Not yet recruiting Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Conditions: Bone Metastases;   HER2-positive Breast Cancer;   Liver Metastases;   Lung Metastases;   Recurrent Breast Cancer;   Soft Tissue Metastases;   Stage IV Breast Cancer
Interventions: Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography;   Biological: trastuzumab;   Radiation: copper Cu 64-DOTA-trastuzumab;   Biological: ado-trastuzumab emtansine;   Other: laboratory biomarker analysis
5 Active, not recruiting A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
Condition: Advanced Breast Cancer
Interventions: Drug: HKI-272;   Drug: Herceptin
6 Completed Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
Conditions: Breast Cancer;   Breast Neoplasms
Interventions: Drug: XL147 (SAR245408);   Biological: trastuzumab;   Drug: paclitaxel
7 Completed Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Condition: Carcinoma, Metastatic Breast
Interventions: Drug: CPG 7909;   Drug: Herceptin®
8 Completed Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Drug: carboplatin;   Drug: docetaxel;   Biological: trastuxumab;   Drug: Docetaxel
9 Completed CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
Condition: Carcinoma, Breast
Interventions: Drug: 0.04 mg/kg CpG 7909;   Drug: Herceptin®;   Drug: 0.08 mg/kg CpG 7909;   Drug: 0.12 mg/kg CpG 7909;   Drug: 0.16 mg/kg CpG 7909
10 Unknown  MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
Conditions: HER2 Amplified Breast Cancer;   Metastatic or Advanced Breast Cancer
Intervention: Drug: MM-111 and Herceptin
11 Completed A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)
Condition: Healthy
Interventions: Biological: PF-05280014;   Biological: Herceptin
12 Completed
Has Results
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Conditions: Breast Cancer;   Neoplasm Metastasis
Interventions: Drug: Trastuzumab;   Drug: RAD001
13 Active, not recruiting A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Condition: Breast Cancer
Interventions: Drug: docetaxel;   Drug: paclitaxel;   Drug: pertuzumab;   Drug: pertuzumab-placebo;   Drug: trastuzumab [Herceptin];   Drug: trastuzumab emtansine
14 Active, not recruiting A Study to Compare Subcutaneous Versus Intravenous Administration of Herceptin (Trastuzumab) in Women With HER2-Positive Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: 5-fluorouracil;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: epirubicin;   Drug: trastuzumab [Herceptin]
15 Recruiting A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2-Positive Metastatic Breast Cancer Patients
Condition: HER2-positive Metastatic Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Paclitaxel
16 Terminated Neoadjuvant Herceptin in Patients With Breast Cancer
Condition: BREAST CANCER
Intervention: Drug: Herceptin
17 Recruiting A Study of Patient Preference for Subcutaneous Versus Intravenous Herceptin (Trastuzumab) in Patients With HER2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Herceptin for at Least 3 Years
Condition: Breast Cancer
Intervention: Drug: trastuzumab [Herceptin]
18 Recruiting Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: entinostat;   Drug: lapatinib ditosylate;   Biological: trastuzumab;   Other: laboratory biomarker analysis
19 Terminated Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Gemcitabine;   Drug: Herceptin;   Drug: Capecitabine (Xeloda)
20 Recruiting Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Condition: Breast Neoplasms
Interventions: Drug: Trastuzumab;   Drug: pertuzumab;   Drug: lapatinib

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years